E- ISSN: 2348-3962, P-ISSN: 2394-5583



Received on 02 May 2020; received in revised form, 23 September 2020; accepted, 25 September 2020; published 01 October 2020

# HERBAL MEDICINES IN MANAGEMENT AND PREVENTION OF CORONAVIRUS DISEASE 2019 (COVID-19)

Ritay Brahmbhatt

Vardhman Raw House, Opp. Shankeshwar App, New Kosad Road, Amroli, Surat - 394107, Gujarat, India.

### **Keywords:**

Traditional Herbal Medicine, COVID-19, AntiCOV-19, Structural levels, RNA synthesis, *Tribulus* terrestris, Withania somnifera, Curcuma longa, Ocimum sanctum, Phyllanthus emblica

## Correspondence to Author: Ritay Brahmbhatt

Vardhman Raw House, Opp. Shankeshwar App, New Kosad Road, Amroli, Surat - 394107, Gujarat, India.

**E-mail:** ritavbrahmbhatt@gmail.com

ABSTRACT: Traditional herbal medicines are widely accepted in the world. Certain countries and WHO have research investment in traditional herbal medicines. Coronavirus disease 2019 (COVID-19) came as a major health care challenge for humans in 2019. 480 deaths have been recorded till 18<sup>th</sup> of April 2020 in India. No pharmaceutical products have yet been shown to be safe and effective for the treatment of COVID-19. Major 3 types of targets of Coronavirus were identified by researches, which are as follow-1) Inhibit coronavirus at a structural level, 2) Inhibit Coronavirus RNA synthesis and replication and 3) inhibit virulence factor of Coronavirus. Certain herbal medicines like *Tribulus terrestris*, *Withania somnifera*, *Curcuma longa*, *Ocimum sanctum*, and *Phyllanthus emblica* have potent anti-viral (Anti-COV-19) properties against novel Coronavirus, which is indicating new sunrise in the direction of herbal medicine.

**INTRODUCTION:** Traditional herbal medicines are getting significant attention in global health debates. India, The United States of America (USA), China, Nigeria, and the World Health Organization (WHO) have all made substantial research investments in traditional herbal medicines <sup>1</sup>. Herbal medicine finds itself in a race to develop new medicines, with fewer or no adverse effects, for therapeutic and preventive application in illnesses <sup>2</sup>. As per the Ministry of Health and Family Welfare, Government of India, there are 11, 906 Active Cases of COVID-19. 480 deaths have been reported, 1991 patients were discharged till 18<sup>th</sup> April 2020 <sup>3</sup>.



DOI: 10.13040/IJPSR.0975-8232.IJP.7(10).240-43

The article can be accessed online on www.ijpjournal.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.7(10).240-43

But still, no pharmaceutical products have yet been shown to be safe and effective for the treatment of Coronavirus (COV-19). However, a number of medicines have been suggested as potential investigational therapies, many of which are now being or will soon be studied in clinical trials, including the SOLIDARITY trial co-sponsored by WHO and participating countries <sup>4</sup>.

### **MATERIALS AND METHODS:**

**Bibliographical Databases:** Google Scholar, PubMed, Preprint, ChemRxiv.

**Search Terms:** Herbal medicine, COVID-19, *invitro*, *in-vivo*, preclinical, clinical trials.

## **Search Strategies:**

- ➤ Phytoconstituents and its effectiveness against COV-19.
- ➤ Herbal medicine and its binding sites to COV-19.

#### E- ISSN: 2348-3962, P-ISSN: 2394-5583

## **Selection Criteria:**

**Inclusion:** Phytomedicine and its binding capacity with COV-19 (Primary virtual examination). *Invitro* and *in-vivo* studies associated with COV-19

#### **Exclusion:**

- Clinical trials (due to lack of research)
- Unknown source of Herbal Medicine

## Major 3 Types of Targets of COV-19: <sup>5</sup>

❖ The number of studies included: 25

- 1. Inhibit Coronavirus at a structural level.
- 2. Inhibit Coronavirus RNA synthesis and replication.

The number of studies screened more than 500

3. Inhibit the virulence factor of Coronavirus.

## 1.1 Major Targets of COV-19:

TABLE 1: ENLIST THE MAJOR TARGETS OF COVID-19

<u> </u>	G					
S. no.	Major Targets of COV-19 <sup>5</sup>					
#	Inhibit SARS-CoV-2 RNA Synthesis and	Inhibit SARS-CoV-2 at	<b>Inhibit Virulence Factor of</b>			
	Replication	Structural Level	SARS-CoV-2			
1	Papain-like protease (PLpro) <sup>5</sup>	Spike Protein <sup>5</sup>	Nsp1 <sup>5</sup>			
2	3C-like main protease (3CLpro) <sup>5</sup>	E protein Or N protein <sup>5</sup>	Nsp3c <sup>5</sup>			
3	RNA-dependent RNA polymerase (RdRp) <sup>5</sup>	-	ORF7 <sup>5</sup>			
4	Helicase <sup>5</sup>	-	-			

- **1.2 Effective Herbal Plants against COVID-19:** Certain natural products from Indian natural medicines bind to the active sites of COV-19 proteases, hence are likely to hinder viral replication <sup>6</sup>.
- **1.2.1** *Tribulus terrestris: Tribulus terrestris* fruits are well known for their usage in pharmaceutical preparations and food supplements. The methanol extract of *T. terrestris* fruits showed potent inhibition against the papain-like protease (PLpro), an essential proteolytic enzyme for protection to pathogenic viruses and bacteria. Major bioactive compounds, aresix cinnamic amides, and ferulic acid were showing inhibition of Papain-like protease (PLpro), which is the major protein target of COV-19.(7)
- 1.2.2 Withania somnifera: Withania somnifera contains a variety of phytoconstituents like Withanolide A & B, Withaferin A, Withanone, Withanosides 8. W. somnifera glycoprotein (WSG) isolated from W. somnifera root tubers revealed (protease inhibitor) antimicrobial activity against few bacterial and phytopathogenic virus 9. W. somnifera would be an effective agent in the management of COV-19 through modulation of host Th-1/Th-2 immunity. W. somnifera may be beneficial in inducing anti-viral immunity (owing to increased IFN-gamma responses) and optimum anti-inflammatory activities (down-regulation of IL-1, IL-6, TNF-alpha and other inflammatory mediators), which are the key targets relevant to

COVID-19 <sup>10</sup>. As per the recent molecular docking studies, Withanolide D, Withaferin A, as most appropriate inhibitors against 3C-like main protease (3CLpro), which can be further explored to test against Coronavirus (COV-19) in preclinical and clinical settings <sup>11</sup>. Withanolide-B, Withanone, and Withaferin - A, major phytochemicals of *W. somnifera* have predicted binding energy lower than the pharmacological inhibitor, N3. The binding of these phytochemicals with the main protease may slow down the cleavage of pseudo-particles (PPs) to releases non-structural proteins (NSPs) and decrease the process of viral replication and transcription <sup>12</sup>.

**1.2.3** *Curcuma longa*: *Curcuma longa* contains demethoxy Curcumin, Curcumin, Diacetyl Curcumin <sup>13</sup>, as a major phytoconstituents, which are the most potent compounds that may act as potential inhibitors of COV-19 Main Protein (Mpro) <sup>14</sup>. Curcumin strongly binds to 3CL-protease of COV-19 in comparison to the antimalarial drugs and promote important structural changes in this viral protease, inducing folding of the enzyme <sup>15</sup>.

Diacetyl Curcumin present in C. longa has been found as more effective on COV-19 (Mpro) than Nelfinavir <sup>16</sup>. Docking studies suggesting that the binding energy of Curcumin (-38.84 kcal/mol) had greater than hydroxychloroquine (HCQ) (-35.87 kcal/mol) in the case of S1 receptor binding domain <sup>17</sup>. As, Curcumin and HCQ interact with the C-

E- ISSN: 2348-3962, P-ISSN: 2394-5583

terminal of S1 domain with different binding energies <sup>18</sup>. Therefore, Curcumin could be used as combination therapy along with hydroxylchloroquine for disrupting the stability of SARS-CoV2 receptor proteins.

**1.2.4** *Ocimum sanctum*: *Ocimum sanctum* extract can be included as a preventive measure against COVID-19 due to its potential to inhibit replication of COV-19 supported with its immune-modulatory feature and ACE II blocking properties. *O. sanctum* containing Tulsinol (A, B, C, D, E, F, G) and dihydrodieuginol-B inhibit COV-19 Main Protease and Papain-like Protease <sup>9</sup>. *O. sanctum* is being used in the management of pain, diarrhea, cough and fever, which are the common symptoms of

COV-19 <sup>20</sup>. *O. sanctum* boosts the immunity of the body and helps to defend the threatening virus and bacteria <sup>21</sup>.

**1.2.5** *Phyllanthus emblica*: *Phyllanthus emblica* also have immunomodulatory properties and may have the potential to bolster the health and immunity of the community in the fight against COV-19 infection <sup>10</sup>. Phyllaemblicin-B and phyllaemblinol from *P. emblica* showed a high binding affinity to helicase protein, which is one of the major targets of COV-19. Phyllaemblicin G7 from *P. emblica* exhibited a high binding affinity to the Spike Protein of COVID-19 <sup>5</sup>. The antioxidative and anti-inflammatory properties of *P. emblica* are the key to its therapeutic effect <sup>22</sup>.

TABLE 2: HERBAL MEDICINES AND ITS EFFECTIVE TARGETS AGAINST COV-19

S. no.	Herbal Medicines	Effective Targets of COV-19	References	
1	T. terrestris	Papain-like protease (PLpro)	(7)	
2	W. somnifera	3C-like Main protease (3CLpro)	(11)	
3	C. longa	3C-like Main protease (3CLpro)	(15)	
4	O. sanctum	Main Protease and Papain-like Protease.	(19)	
5	P. emblica	Helicase protein and Spike Protein	(5)	

**CONCLUSION:** Novel evidence based approach of herbal medicine plays preventive role in the COVID-19 pandemic. Naturally occurring plants are source of wide variety of phytoconstituents. *Tribulus terrestris*, *Withania somnifera*, *Curcuma longa*, *Ocimum sanctum*, *Phyllanthus emblicaare* primarily observed as effective against COVID-19. Moreover, *in-vitro* and *in-vivo* studies require to-identify the efficacy of herbal medicine.

However, Combination therapies of allopath and herbal medicines lead towards the best treatment options. Still, many unknown herbals medicines are waiting for their identification and purification and pharmaceutical evaluation. There is a major research gap between the primary effectiveness of herbal medicine and its clinical trials. Further, research can be carried out on the basis of *in-vitro* and *in-vivo* studies, along with preclinical and clinical reports.

#### **ACKNOWLEDGEMENT:** Nil

## **CONFLICTS OF INTEREST: Nil**

## **REFERENCES:**

 World Health Organization. 2008 Herbal medicine research and global health: an ethical analysis https://www. who.int/bulletin/volumes/86/8/07-042820/en/.

- 2. Wagner H: Pure and Applied Chemistry Natural products chemistry and phytomedicine in the 21<sup>st</sup> century: New developments and challenges. Pure and Applied Chemistry 2009; 77(1):
- 3. MoHFW Home. (2020). Retrieved 18 April 2020, from https://www.mohfw.gov.in/
- World Health Organization. (2018) Monitored emergency use of unregistered and experimental interventions (MEURI),http://www.who.int/ethics/publications/infectiou s-disease-outbreaks/en/
- Wu C, Liu Y, Yang Y, Zhang P, Zhong W and Wang Y: Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. 2020.
- Hastantram M and Ramaiah S: Molecular docking analysis
  of selected natural products from plants for inhibition of
  SARS-CoV-2 main protease. Current Science 2020;
  118(7): 1087-92.
- 7. Song Y, Kim D and Curtis-Long M: Papain-like protease (PLpro) inhibitory effects of cinnamic amides from *Tribulus terrestris* fruits. Biol Pharm Bull 2014; 37(6): 1021-28.
- 8. Dwivedi D and Thanwar M: Study of phytochemical active compounds in extract of *Withania somnifera*. Rasāyan Journal 2015; 8(4): 522-26.
- 9. Mahesh B: Antimicrobial activity of some important medicinal plant against plant and human pathogens. World Journal of Agricultural Sciences 2008; 4: 839-43.
- Patwardhan B, Chavan-Gautam P, Gautam M, Tillu G and Chopra A: Ayurveda rasayana in prophylaxis of COVID-19. Current Science 2020; 118(3): 1-3.
- Chandel V, Raj S and Rathi B: *In-silico* identification of potent COVID-19 main protease inhibitors from fda approved antiviral compounds and active phytochemicals through molecular docking. A Drug Repurposing Approach Preprint 2020; 1.

- Maurya D and Sharma D: Evaluation of traditional ayurvedic preparation for prevention and management of the Novel Coronavirus (SARS-CoV-2) using molecular docking approach. Chem Rxiv Preprint 2020.
- 13. Dosoky N and Setzer W: Chemical composition and biological activities of essential oils of *Curcuma species*. Nutrients 2018; 10: 1196.
- 14. Khaerunnisa S, Kurniawan H: Potential inhibitor of COVID-19 main protease (Mpro) from Several Medicinal Plant Compounds by Molecular Docking Study 2020. http://www.lavierebelle.org/IMG/pdf/2020\_potential\_inhib itorofcovid19mainproteasefromseveralmedicinalplantcomp ounds.pdf.
- 15. Gonzalez LA, Lossada CA and Moncayo LS: Theoretical molecular docking study of the structural disruption of the viral 3cl-protease of COVID19 induced by binding of capsaicin, piperine and curcumin part 1: a comparative study with chloroquine and hydrochloroquine two antimalaric drugs. Research Square Preprint 2020; 1.
- Adem S, Eyupoglu V, Sarfraz I, Rasul A and Ali M: Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA. Preprints 2020; 21: 1.

- Srivastava A and Singh D: Destabilizing the structural integrity of SARS-CoV2 receptor proteins by *Curcumin Along* with Hydroxychloroquine. An Insilco Approach for a Combination Therapy Chem Rxiv 2020; 29: 2.
- Rane J and Chatterjee A: Targeting SARS-CoV-2 spike protein of COVID-19 with Naturally Occurring phytochemicals: an *in-silco* study for drug development. Chemrxiv 2020.
- Varshney K, Varshney M and Nath B: Molecular modeling of isolated phytochemicals from *Ocimum* sanctum towards exploring potential inhibitors of SARS Coronavirus Main Protease and Papain-Like Protease to Treat COVID-19. Preprints 2020; 98: 1.
- Goothy S, Choudhary A, Potey G, Chakraborty H, Kumar A and Mahadik V: Ayurveda's Holistic Lifestyle Approach for the Management of Coronavirus disease (COVID-19): Possible Role of Tulsi. International Journal of Research in Pharmaceutical Sciences 2020; 11: 16-18.
- Mondal S, Varma S, Bamola D, Naik N, Mirdha R, Padhi M and Mahapatra C: Double-blinded randomized controlled trial for immunomodulatory effects of Tulsi (*Ocimum sanctum* Linn.) leaf extract on healthy volunteers. J of Ethnopharmacology 2011; 136(3): 452-56.

#### How to cite this article:

Brahmbhatt R: Herbal medicines in management and prevention of Ccoronavirus disease 2019 (COVID-19). Int J Pharmacognosy 2020; 7(10): 240-43. doi link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.7(10).240-43.

This Journal licensed under a Creative Commons Attribution-Non-commercial-Share Alike 3.0 Unported License.

This article can be downloaded to Android OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)